12:00 AM
 | 
Oct 29, 2012
 |  BC Week In Review  |  Company News  |  Deals

Biotecnol Inc., PolyTherics deal

Biotecnol and PolyTherics partnered to develop multi-specific Tribody drug conjugates to treat cancer. The companies will use PolyTherics' ThioBridge conjugation technology to attach cytotoxic drugs on Biotecnol's...

Read the full 111 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >